HK1047036A1 - 用於治疗偏头痛的选择性iglur5，受体拮抗剂 - Google Patents

用於治疗偏头痛的选择性iglur5，受体拮抗剂 Download PDF

Info

Publication number
HK1047036A1
HK1047036A1 HK02107174.1A HK02107174A HK1047036A1 HK 1047036 A1 HK1047036 A1 HK 1047036A1 HK 02107174 A HK02107174 A HK 02107174A HK 1047036 A1 HK1047036 A1 HK 1047036A1
Authority
HK
Hong Kong
Prior art keywords
sub
receptor antagonists
migraine
treatment
selective
Prior art date
Application number
HK02107174.1A
Other languages
English (en)
Chinese (zh)
Inventor
Bleakman David
Suzon Chappell Amy
Ann Filla Sandra
Willis Johnson Kirk
Leslie Ornstein Paul
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HK1047036A1 publication Critical patent/HK1047036A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK02107174.1A 1999-07-06 2000-06-27 用於治疗偏头痛的选择性iglur5，受体拮抗剂 HK1047036A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US60/142,485 1999-07-06
US15116599P 1999-08-27 1999-08-27
US60/151,165 1999-08-27
PCT/US2000/016297 WO2001001972A2 (en) 1999-07-06 2000-06-27 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE

Publications (1)

Publication Number Publication Date
HK1047036A1 true HK1047036A1 (zh) 2003-02-07

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02107174.1A HK1047036A1 (zh) 1999-07-06 2000-06-27 用於治疗偏头痛的选择性iglur5，受体拮抗剂

Country Status (28)

Country Link
US (4) US6566370B1 (enExample)
EP (1) EP1200073B1 (enExample)
JP (1) JP4619595B2 (enExample)
KR (1) KR20020024300A (enExample)
CN (1) CN1230174C (enExample)
AR (1) AR029373A1 (enExample)
AU (1) AU773304B2 (enExample)
BR (1) BR0012175A (enExample)
CA (1) CA2378613C (enExample)
CZ (1) CZ20014488A3 (enExample)
DE (1) DE60032905T2 (enExample)
DK (1) DK1200073T3 (enExample)
DZ (1) DZ3209A1 (enExample)
EA (1) EA004290B1 (enExample)
ES (1) ES2278619T3 (enExample)
HK (1) HK1047036A1 (enExample)
HR (1) HRP20020013A2 (enExample)
HU (1) HUP0202253A3 (enExample)
IL (1) IL146697A0 (enExample)
MX (1) MXPA01012726A (enExample)
MY (1) MY133503A (enExample)
NO (1) NO20016246L (enExample)
NZ (1) NZ515616A (enExample)
PE (1) PE20010299A1 (enExample)
PT (1) PT1200073E (enExample)
SK (1) SK112002A3 (enExample)
TR (1) TR200200066T2 (enExample)
WO (1) WO2001001972A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257545A1 (en) * 1999-12-22 2002-11-20 Eli Lilly And Company SELECTIVE iGLUR 5? RECEPTOR ANTAGONISTS
AU2002227020A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
MXPA03005981A (es) * 2001-01-05 2003-09-10 Lilly Co Eli Antagonistas de receptores de aminoacidos excitatorios.
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
DK1368032T3 (da) * 2001-01-05 2008-09-29 Lilly Co Eli Exitatoriske aminosyrereceptorantagonister
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6855725B2 (en) * 2001-01-05 2005-02-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
BR0308911A (pt) 2002-04-26 2005-01-04 Lilly Co Eli Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
MX2009002002A (es) 2006-08-23 2009-07-22 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8030518B2 (en) 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
JP7399096B2 (ja) 2018-03-05 2023-12-15 ヤンセン ファーマシューティカ エヌ．ベー． 神経変性を検出するためのアッセイ
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
MA56607A1 (fr) 2019-11-08 2022-10-31 Xenon Pharmaceuticals Inc Méthodes de traitement de troubles dépressifs
JP2024508660A (ja) 2021-02-09 2024-02-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
KR20010006075A (ko) 1997-04-07 2001-01-15 피터 지. 스트링거 약제
US6486175B1 (en) * 1999-07-06 2002-11-26 Eli Lilly And Company Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid

Also Published As

Publication number Publication date
EA004290B1 (ru) 2004-02-26
PT1200073E (pt) 2007-03-30
EA200200132A1 (ru) 2002-06-27
MXPA01012726A (es) 2002-07-02
DE60032905T2 (de) 2007-10-18
CN1359289A (zh) 2002-07-17
JP2003503449A (ja) 2003-01-28
KR20020024300A (ko) 2002-03-29
US6566370B1 (en) 2003-05-20
CA2378613C (en) 2007-10-02
CZ20014488A3 (cs) 2003-01-15
NO20016246L (no) 2002-03-04
ES2278619T3 (es) 2007-08-16
US20050159445A1 (en) 2005-07-21
US20030199546A1 (en) 2003-10-23
US20040192722A1 (en) 2004-09-30
WO2001001972A3 (en) 2001-12-06
BR0012175A (pt) 2002-03-05
US6855823B2 (en) 2005-02-15
PE20010299A1 (es) 2001-03-07
US7157582B2 (en) 2007-01-02
AU5873200A (en) 2001-01-22
DK1200073T3 (da) 2007-05-07
DZ3209A1 (fr) 2001-01-11
CA2378613A1 (en) 2001-01-11
EP1200073B1 (en) 2007-01-10
SK112002A3 (en) 2003-05-02
HUP0202253A3 (en) 2003-12-29
MY133503A (en) 2007-11-30
HRP20020013A2 (en) 2003-08-31
TR200200066T2 (tr) 2002-04-22
IL146697A0 (en) 2002-07-25
EP1200073A2 (en) 2002-05-02
JP4619595B2 (ja) 2011-01-26
US6759418B2 (en) 2004-07-06
AR029373A1 (es) 2003-06-25
NO20016246D0 (no) 2001-12-19
AU773304B2 (en) 2004-05-20
CN1230174C (zh) 2005-12-07
HUP0202253A2 (hu) 2002-11-28
NZ515616A (en) 2004-05-28
WO2001001972A2 (en) 2001-01-11
DE60032905D1 (de) 2007-02-22

Similar Documents

Publication Publication Date Title
HK1047036A1 (zh) 用於治疗偏头痛的选择性iglur5，受体拮抗剂
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
EP0715855A3 (en) NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO1996015786A3 (en) Oral compositions containing ondansetron
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
HUP0204049A3 (en) Compositions of combined active ingredients for treating glaucoma
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
WO1999061059A8 (en) Minoxidil compositions for external use
WO2000048446A3 (en) Use of antagonists of pg-e for the treatment of neuropathic pain
WO2004067510A8 (en) 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2001087862A3 (en) Biologically active 4h-benzo[1,4]oxazin-3-ones
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
EP2140864A3 (en) Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods
AU7476501A (en) New use of angiotensin ii antagonists
WO2002053099A3 (en) Methods and compositions for treating periodontal disease
GB0019008D0 (en) Therapeutic compounds
WO2001043761A3 (en) Methods for treating and preventing damage to mucosal tissue
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
WO2000076457A3 (en) Il-8 receptor antagonists
WO2000061230A3 (en) Estrogen receptors-beta antagonism and bone diseases
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine